全文获取类型
收费全文 | 8374篇 |
免费 | 542篇 |
国内免费 | 58篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 201篇 |
妇产科学 | 225篇 |
基础医学 | 1308篇 |
口腔科学 | 51篇 |
临床医学 | 792篇 |
内科学 | 2019篇 |
皮肤病学 | 145篇 |
神经病学 | 810篇 |
特种医学 | 249篇 |
外科学 | 1486篇 |
综合类 | 39篇 |
一般理论 | 3篇 |
预防医学 | 524篇 |
眼科学 | 89篇 |
药学 | 453篇 |
中国医学 | 7篇 |
肿瘤学 | 531篇 |
出版年
2023年 | 43篇 |
2022年 | 79篇 |
2021年 | 171篇 |
2020年 | 111篇 |
2019年 | 167篇 |
2018年 | 213篇 |
2017年 | 150篇 |
2016年 | 151篇 |
2015年 | 200篇 |
2014年 | 292篇 |
2013年 | 396篇 |
2012年 | 582篇 |
2011年 | 596篇 |
2010年 | 379篇 |
2009年 | 340篇 |
2008年 | 547篇 |
2007年 | 577篇 |
2006年 | 573篇 |
2005年 | 546篇 |
2004年 | 575篇 |
2003年 | 552篇 |
2002年 | 581篇 |
2001年 | 45篇 |
2000年 | 62篇 |
1999年 | 74篇 |
1998年 | 124篇 |
1997年 | 97篇 |
1996年 | 88篇 |
1995年 | 75篇 |
1994年 | 67篇 |
1993年 | 56篇 |
1992年 | 45篇 |
1991年 | 28篇 |
1990年 | 27篇 |
1989年 | 32篇 |
1988年 | 20篇 |
1987年 | 31篇 |
1986年 | 28篇 |
1985年 | 22篇 |
1984年 | 29篇 |
1983年 | 22篇 |
1982年 | 31篇 |
1981年 | 32篇 |
1980年 | 15篇 |
1979年 | 11篇 |
1978年 | 13篇 |
1977年 | 10篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1974年 | 9篇 |
排序方式: 共有8974条查询结果,搜索用时 16 毫秒
171.
172.
Assessment of atrial septal defect size with 3D-transesophageal echocardiography: comparison with balloon method 总被引:4,自引:0,他引:4
Abdel-Massih T Dulac Y Taktak A Aggoun Y Massabuau P Elbaz M Carrié D Acar P 《Echocardiography (Mount Kisco, N.Y.)》2005,22(2):121-127
BACKGROUND: Transcatheter closure of atrial septal defect (ASD) is an alternative approach to surgery in selected patients. Balloon stretched diameter (BSD) is considered as the standard way of measuring ASD size. Three-dimensional transesophageal echocardiography (3D-TEE) provides views of the ASD allowing its measurement and identifying its spatial relation with neighboring structures. Our aim was to compare the BSD and 3D-TEE methods to measure the ASD size before transcatheter closure. METHODS AND RESULTS: Seventy-six consecutive patients were enrolled for ASD device closure. Three-dimensional transesophageal echocardiography and balloon sizing were adequately performed in 70 patients before the defect closure. The mean maximal diameter measured by 3D-TEE was 20 +/- 15 mm (range 10-28) while the mean BSD was 22 +/- 4.8 mm (range 9-31). When comparing the 3D-TEE and transcatheter measurements, there was a good correlation between the two methods (y = 3.15 + 0.77x; r = 0.8). The defect as viewed by 3D-TEE was unique in 54 patients and multiple in 16 patients. In patients with a single defect, the correlation between the two methods was high (y = 1.74 + 0.84x; r = 0.85) while patients with multiple ASDs, the correlation was poor (y = 12.4 + 0.4x; r = 0.45). Transcatheter closure was performed successfully in 86%. The mean size of the Amplatzer device was 23 +/- 4.8 mm (range 4-32). The reference to choose the size of the device was the BSD in single defects and the 3D-TEE maximal diameter in multiple defects. CONCLUSION: Three-dimensional transesophageal echocardiography and transcatheter methods are two complementary techniques for the success of transcatheter ASDs closure. 相似文献
173.
Merle H Donnio A Ayeboua L Plumelle Y Smadja D Thomas L 《The American journal of tropical medicine and hygiene》2005,73(3):583-585
We report a case of snakebite in which envenomation was manifested through impairment of the visual field. The patient, a 46-year-old man, was bitten on the right thumb by Bothrops lanceolatus. Treatment with a specific equine antivenom (Bothrofav) was administered one hour after the bite. With the exception of fang marks, the results of a clinical examination, particularly the neurologic component, were normal. The day after the bite, the patient developed an inferior left lateral homonymous quadranopsia with macular epargne. T2 magnetic resonance imaging showed a right occipital infarction. His condition improved clinically and biologically. This observation of snakebite is the first in which envenomation was accompanied exclusively by an impairment of the visual field. Envenomation by B. lanceolatus is distinct in its incidence of significant thrombotic complications at a distance from the site of the bite. 相似文献
174.
Dulac Y Pienkowski C Abadir S Tauber M Acar P 《Archives of Cardiovascular Diseases》2008,101(7-8):485-490
Cardiovascular complications in Turner's syndrome are the most common cause of excess early mortality, with a life expectancy that may be reduced by more than 10 years. Congenital cardiac abnormalities are described in approximately one third of patients. These abnormalities are mostly left heart obstructions, the most common of which are bicuspid aortic valve (16%) and coarctation of the aorta (11%). Dilatations of the ascending aorta are often described and may occur in isolation from any heart disease, suggesting a vasculopathy specific to the syndrome, probably predisposed to by extracardiac risk factors such as oestrogen deficiency, diabetes, dysplidaemia and overweight. The most feared complication is aortic dissection with around a 100 cases, described at average age of approximately 35-years-old. This is believed to complicate 2% of induced pregnancies. Hypertension (HBP) usually essential, affects up to 50% of patients with Turner's syndrome. This is an important risk factor for cardiovascular complications and justifies aggressive treatment. On the other hand, retrospective studies have not demonstrated adverse cardiological effects due to growth hormone treatments. Patients with Turner's syndrome merit regular cardiology follow-up from childhood onwards, particularly if they have treated heart disease. The merits of preventative treatments for aortic dilatation have not been demonstrated in Turner's syndrome and justify prospective trials. 相似文献
175.
Cacoub P Halfon P Rosenthal E Pialoux G Benhamou Y Perronne C Pol S;Prospecth Study Group 《Journal of hepatology》2008,48(1):35-42
BACKGROUND/AIMS: To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006. METHODS: Three hundred and eighty HIV-HCV co-infected patients were prospectively included in surveys from November 22 to 29, 2004 (2004 survey), and 416 from April 3 to 10, 2006 (2006 survey). RESULTS: Patients in 2006 compared to those in 2004 had negative HCV RNA more often (24% vs. 12%). The rate of liver biopsy was similar (56% vs. 54%) while 24% had had a non-invasive liver damage assessment. The rate of previous treatment for HCV infection was higher (48% vs. 26%). The main reasons for HCV non-treatment have changed: HCV treatment deemed questionable (44% vs. 53%), lack of liver biopsy (18% vs. 33%), physicians' conviction of poor patient compliance (20% vs. 30%). In both surveys, HCV treated patients were more often of European origin, had better control of HIV infection, and had a liver damage assessment more often. CONCLUSIONS: The care of HIV-HCV co-infected patients has changed significantly in "real life". These results underline the importance of continuing efforts to educate physicians and patients in order to increase the access of co-infected patients to HCV treatment. 相似文献
176.
Chantal Bottex Yves P. Gauthier Ralf M. Hagen Ernst J. Finke Wolf D. Splettstösser François M. Thibault 《Immunopharmacology and immunotoxicology》2013,35(4):565-583
Melioidosis is a severe gram-negative infection caused by the facultative intracellular bacterium Burkholderia pseudomallei, which is responsible for a broad spectrum of symptoms in both humans and animals. No licensed vaccine currently exists. This study evaluated the protective effect of a monoclonal antibody (Mab Ps6F6) specific to B. pseudomallei exopolysaccharide in an outbred murine model of sub-acute melioidosis. When administered before the infectious challenge, Ps6F6 significantly increased resistance to infection and restrained bacterial burden in the spleen over a 30-days period. Patterns of IFN-γ production were similar in the treated and non treated groups of mice. However, Ps6F6 lowered IFN-γ levels over the duration of the assay period, except on day 1, suggesting a transient and rapid production of IFN-γ under Ps6F6 control. Minor but persisting increases occurred in IL-12 levels while TNF-α was detected only in the controls at the later stages of infection. No IL-10 secretion was detected in both groups of mice. These data suggest that passive prophylaxis with Mab Ps6F6 provide a moderate and transient induction of inflammatory responses in infected mice but failed to trigger a sterilizing protective immunity. 相似文献
177.
Christoph Käcker Alexander Marx Katharina Mössinger Frederike Svehla Ulrike Schneider Pancras Cornelis Wilhelmus Hogendoorn Ole Steen Nielsen Stefan Küffer Christian Sauer Cyril Fisher Christian Hallermann Jörg Thomas Hartmann Jean‐Yves Blay Gunhild Mechtersheimer Peter Hohenberger Philipp Ströbel 《Genes, chromosomes & cancer》2013,52(1):93-98
Irradiation is a major causative factor among the small subgroup of sarcomas with a known etiology. The prognosis of radiation‐induced sarcomas (RIS) is significantly worse than that of their spontaneous counterparts. The most frequent histological subtypes include undifferentiated pleomorphic sarcomas, angiosarcomas, and leiomyosarcomas. A high frequency of MYC amplifications in radiation‐induced angiosarcomas, but not in primary angiosarcomas, has recently been described. To investigate whether MYC amplifications are also frequent in RIS other than angiosarcomas, we analyzed the MYC amplification status of 83 RIS and 192 sporadic sarcomas by fluorescence in situ hybridization. We found significantly higher numbers of MYC amplifications in RIS than in sporadic sarcomas (P < 0.0001), especially in angiosarcomas, undifferentiated pleomorphic sarcomas, and leiomyosarcomas. Angiosarcomas were special in that MYC amplifications were particularly frequent and always high level, while other RIS showed low‐level amplifications. We conclude that MYC amplifications are a frequent feature of RIS as a group and may contribute to the biology of these tumors. © 2012 Wiley Periodicals, Inc. 相似文献
178.
Patrick Blin Caroline Dureau-Pournin Jacques Bnichou Yves Cottin Patrick Mismetti Abdelilah Abouelfath Regis Lassalle Ccile Droz Nicholas Moore 《Am J Cardiovasc Drugs》2020,20(1):81-103
Clinical trials have indicated that the direct-acting oral anticoagulants dabigatran and rivaroxaban have better risk/benefit profiles than do vitamin K antagonists (VKAs) for stroke prevention in non-valvular atrial fibrillation (NVAF). Our objective was to compare the 1-year real-life risk of major clinical events with dabigatran or rivaroxaban versus VKAs for NVAF. This was a high-dimensional propensity score (hdPS)-matched cohort study of new users of dabigatran, rivaroxaban or VKAs for NVAF in the French national healthcare systems database in 2013 followed-up for 1 year [22]. Hazard ratios (HRs) with 95% confidence intervals (CIs) for clinical events and death were determined during exposure. In 2013, a total of 103,101 new anticoagulant users had definite NVAF: 44,653 VKA, 27,060 dabigatran, and 31,388 rivaroxaban. In matched populations, HRs were as follows for dabigatran versus VKAs (20,489 per group): stroke and systemic embolism (SSE) 0.75 (95% CI 0.63–0.88), clinically relevant bleeding (CRB) 0.58 (95% CI 0.51–0.66), hemorrhagic stroke (HS) 0.22 (95% CI 0.14–0.36), gastrointestinal bleeding (GIB) 0.98 (95% CI 0.80–1.19), acute coronary syndrome (ACS) 0.79 (95% CI 0.65–0.95), death 0.74 (95% CI 0.67–0.82), composite (any of the above) 0.71 (95% CI 0.66–0.76). For matched rivaroxaban versus VKA (23,053 per group) HRs were as follows: SSE 0.98 (95% CI 0.85–1.14), CRB 0.83 (95% CI 0.75–0.92), HS 0.65 (95% CI 0.49–0.87), GIB 1.08 (95% CI 0.90–1.30), ACS 0.84 (95% CI 0.71–1.00), death 0.77 (95% CI 0.71–0.84), composite 0.84 (95% CI 0.79–0.89). Numbers needed to treat to observe one fewer death were 49 ± 0.05 with dabigatran or rivaroxaban versus VKAs. Consistent with results from clinical trials and other observational studies, dabigatran and rivaroxaban were at least as effective and safer than VKAs for the prevention of thromboembolic events in NVAF over 1 year in the French population. European Medicines Agency EUPAS 13017 (www.encepp.eu) Clinicaltrials.gov id NCT02785354. 相似文献
179.
180.